Related Experiment Video
Updated: Jun 18, 2026
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Toni K Choueiri1, Michael B Atkins
1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Nature Reviews. Clinical Oncology
|November 28, 2009
Summary
Sunitinib is a standard first-line treatment for advanced clear-cell renal cell carcinoma. An expanded-access study confirmed its clinical benefit and acceptable safety in a real-world patient population.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced or metastatic clear-cell renal cell carcinoma (ccRCC) requires effective first-line therapies.
- Sunitinib is an established treatment option for this patient group.
Purpose of the Study:
- To evaluate the clinical benefit and safety of sunitinib in a broad patient population with advanced or metastatic ccRCC.
- To assess sunitinib's real-world effectiveness and tolerability in a representative clinical setting.
Main Methods:
- An expanded-access study design was employed.
- Data were collected from patients receiving sunitinib as first-line therapy for advanced or metastatic ccRCC.
Main Results:
- Sunitinib demonstrated clinical benefit in the studied patient population.
- The safety profile of sunitinib was found to be acceptable.
Conclusions:
- Sunitinib provides clinical benefit with an acceptable safety profile for patients with advanced or metastatic clear-cell renal cell carcinoma.
- The findings support the use of sunitinib in routine clinical practice for this indication.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...